Drug helps reduce breast cancer recurrence
Drug helps reduce breast cancer recurrence
By
Newsfeed display by CaRP WHEN the US Food and Drug Administration first approved the drug raloxifene in December 1997, it was indicated to help prevent and treat thinning of the bones, or osteoporosis, in postmenopausal women.
This may soon change in the light of a recent finding that the drug has an added benefit: it significantly reduces the risk for developing breast cancer.
After four years, the Continuing Outcomes Relevant to Evista (Core) trial showed that the incidence of invasive breast cancer for women taking raloxifene was reduced by 59 percent compared with women taking a placebo, and the incidence of estrogen-receptor (ER)-positive invasive breast cancer was reduced by 66 percent.
\\"This finding is promising since the trial has shown the drug\\'s long-term effectiveness in reducing breast cancer recurrence,\\" said Lotis Calinawan of Eli Lilly, which markets the drug under the trade name of Evista.
The Core study is actually a continuation of Multiple Outcomes of Raloxifene Evaluation (More) trial, which assessed the drug\\'s effectiveness in treating osteoporosis as well as its effectiveness in reducing breast cancer risk.
The More trial, which also lasted four years, found the incidence of breast cancer to be 72 percent lower in women taking raloxifene than in women taking a placebo.
The Core trial was designed to examine the effect of an additional four years of treatment with the same drug in the same group of women.
Over the entire eight years of more and Core, the incidence of invasive breast cancer and ER-positive invasive breast cancer were reduced by 66 percent and 76 percent, respectively.
Invasive breast cancer refers to cancer cells that have broken through the mammary duct and have spread to nearby normal tissues while ER-positive breast cancer refers to cancer cells that need the hormone estrogen to grow.
Breast cancer is the second leading cause of cancer deaths in women today, after lung cancer.
According to the World Health Organization, more than 1.2 million people will be diagnosed with breast cancer this year worldwide.
0/5 based on 0 votes. The median rating is 0.
By
Newsfeed display by CaRP WHEN the US Food and Drug Administration first approved the drug raloxifene in December 1997, it was indicated to help prevent and treat thinning of the bones, or osteoporosis, in postmenopausal women.
Print
ReportThis may soon change in the light of a recent finding that the drug has an added benefit: it significantly reduces the risk for developing breast cancer.
After four years, the Continuing Outcomes Relevant to Evista (Core) trial showed that the incidence of invasive breast cancer for women taking raloxifene was reduced by 59 percent compared with women taking a placebo, and the incidence of estrogen-receptor (ER)-positive invasive breast cancer was reduced by 66 percent.
\\"This finding is promising since the trial has shown the drug\\'s long-term effectiveness in reducing breast cancer recurrence,\\" said Lotis Calinawan of Eli Lilly, which markets the drug under the trade name of Evista.
The Core study is actually a continuation of Multiple Outcomes of Raloxifene Evaluation (More) trial, which assessed the drug\\'s effectiveness in treating osteoporosis as well as its effectiveness in reducing breast cancer risk.
The More trial, which also lasted four years, found the incidence of breast cancer to be 72 percent lower in women taking raloxifene than in women taking a placebo.
The Core trial was designed to examine the effect of an additional four years of treatment with the same drug in the same group of women.
Over the entire eight years of more and Core, the incidence of invasive breast cancer and ER-positive invasive breast cancer were reduced by 66 percent and 76 percent, respectively.
Invasive breast cancer refers to cancer cells that have broken through the mammary duct and have spread to nearby normal tissues while ER-positive breast cancer refers to cancer cells that need the hormone estrogen to grow.
Breast cancer is the second leading cause of cancer deaths in women today, after lung cancer.
According to the World Health Organization, more than 1.2 million people will be diagnosed with breast cancer this year worldwide.
|
Rating:
0/5 based on 0 votes. The median rating is 0.
Submitted: 06/05/06
Description:
Breast cancer is the second leading cause of cancer deaths in women today, after lung cancer.
Views:
173 views. Averaging 0 per day.
In the most recent 30 day period, there've been 9 views.
Related Articles:
